Last Updated: November 16, 2026

Investigational Drug Information for Intepirdine

« Back to Dashboard


What is the drug development status for Intepirdine?

Intepirdine is an investigational drug.

There have been 5 clinical trials for Intepirdine. The most recent clinical trial was a Phase 3 trial, which was initiated on April 26th 2016.

The most common disease conditions in clinical trials are Lewy Body Disease, Dementia, and Alzheimer Disease. The leading clinical trial sponsors are Axovant Sciences Ltd. and [disabled in preview].

Recent Clinical Trials for Intepirdine
TitleSponsorPhase
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With DementiaAxovant Sciences Ltd.Phase 2
Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB ExtensionAxovant Sciences Ltd.Phase 2/Phase 3
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET ExtensionAxovant Sciences Ltd.Phase 3

See all Intepirdine clinical trials

Clinical Trial Summary for Intepirdine

Top disease conditions for Intepirdine
Top clinical trial sponsors for Intepirdine

See all Intepirdine clinical trials

Intepirdine Development Update, Patent Status and Market Projection

Last updated: September 5, 2026

Intepirdine, also known as RVT-101, is a discontinued investigational 5-HT6 receptor antagonist developed for symptomatic treatment of Alzheimer’s disease. Its pivotal Phase 3 MINDSET trial failed to improve cognition or activities of daily living in patients receiving background donepezil. Axovant discontinued development in September 2017. Intepirdine has no FDA approval, no marketed product, no Orange Book listing, no established generic-entry pathway, and no current commercial revenue base. Its post-2017 market projection is effectively zero.

What is the current development status of intepirdine?

Intepirdine is no longer in clinical development. Axovant Sciences stopped the program after the MINDSET Phase 3 study failed its primary efficacy endpoints in 2017. No subsequent clinical program, regulatory filing, or commercial relaunch has restored the asset.

Development item Status
Active ingredient Intepirdine, RVT-101
Pharmacologic class Selective 5-HT6 receptor antagonist
Original target disease Mild-to-moderate Alzheimer’s disease
Lead developer Axovant Sciences
Key trial Phase 3 MINDSET
Trial identifier NCT02585934
Phase 3 result Failed primary endpoints
FDA approval None
Commercial launch None
Current development status Discontinued
Current revenue $0 from product sales

The MINDSET study evaluated intepirdine added to stable donepezil therapy. The trial enrolled approximately 1,300 patients with mild-to-moderate Alzheimer’s disease and assessed cognition and daily functioning over 24 weeks. Intepirdine did not produce a statistically significant improvement over placebo on the prespecified primary endpoints. Axovant announced that it would not pursue further development in Alzheimer’s disease or other indications after the result (Axovant Sciences, 2017; ClinicalTrials.gov, n.d.).

What happened in the MINDSET Phase 3 trial?

The MINDSET trial was designed to test whether blocking the 5-HT6 receptor could improve cognitive performance and functional outcomes when added to donepezil.

Trial characteristic MINDSET
Population Mild-to-moderate Alzheimer’s disease
Background treatment Donepezil
Experimental treatment Intepirdine 35 mg
Comparator Placebo
Development phase Phase 3
Primary cognitive measure ADAS-Cog
Primary functional measure ADCS-ADL
Duration Approximately 24 weeks
Outcome No significant benefit on primary endpoints

The failure was commercially decisive because the program lacked a demonstrated efficacy advantage over inexpensive, established cholinesterase inhibitors. The trial did not establish a clinically meaningful effect on cognition, functional decline, or caregiver-relevant outcomes.

The mechanism also faced a high validation burden. 5-HT6 antagonism had generated interest because of its potential effects on cholinergic, glutamatergic, and other neurotransmitter systems. However, a positive mechanistic rationale did not translate into an approvable clinical benefit in MINDSET.

When did intepirdine lose exclusivity and development value?

Intepirdine lost practical development value when Axovant discontinued the program after the September 2017 Phase 3 readout. Patent life became commercially irrelevant because the asset had not demonstrated efficacy and had no regulatory approval.

There is no approved intepirdine product for which FDA marketing exclusivity, new chemical entity exclusivity, pediatric exclusivity, or patent-term extension creates a commercial barrier. The asset therefore has no meaningful FDA exclusivity timeline.

Exclusivity category Intepirdine status
New chemical entity exclusivity Not awarded
FDA approval-based exclusivity None
Pediatric exclusivity None identified
Orphan-drug exclusivity None identified
Orange Book patent listing None
Patent-term extension tied to an approved product None
Generic approval pathway No marketed reference product

What is the FDA and Orange Book status of intepirdine?

Intepirdine is not FDA-approved. It does not appear as an approved reference listed drug in the FDA Orange Book. No abbreviated new drug application can rely on an approved intepirdine product because no such product exists.

The regulatory pathway ended at clinical development. Axovant did not submit a successful new drug application, and the FDA did not grant labeling, marketing authorization, or postmarketing obligations for the compound. The absence of approval eliminates the standard Orange Book framework involving listed patents, Paragraph IV certifications, 30-month stays, and generic launch litigation.

FDA issue Status
IND-stage development Yes
NDA submitted No successful NDA identified
FDA approval No
Orange Book listing No
Approved dosage form None
Approved indication None
Paragraph IV litigation None identified
Authorized generic None

What patents protect intepirdine?

Intepirdine was covered by preclinical and clinical-stage patent rights associated with the compound and its pharmaceutical use. Those rights did not produce an enforceable commercial exclusivity position because no approved product reached the market.

The relevant distinction is between patent rights and regulatory protection. A compound or use patent may remain legally relevant after clinical discontinuation, but it does not create market value without a viable product, regulatory approval, manufacturing capability, and evidence of clinical benefit.

No Orange Book-listed patent estate exists for intepirdine. There is no approved formulation, approved method-of-use claim, or commercial manufacturing process that a generic applicant must challenge through a Paragraph IV certification.

What formulations are protected by intepirdine patents?

Intepirdine was studied as an oral small-molecule drug, including a 35 mg clinical dose in MINDSET. There is no FDA-approved tablet, capsule, extended-release product, liquid formulation, or combination product.

Formulation claims may have existed in development-stage patent filings, but they did not result in a marketed dosage form. No formulation patent creates a current U.S. market barrier comparable to the formulation estates surrounding approved Alzheimer’s therapies.

What method-of-use patents cover intepirdine?

The principal intended use was treatment of cognitive and functional symptoms associated with Alzheimer’s disease, generally as an adjunct to donepezil. Because the clinical program failed, no method-of-use claim became the basis for FDA-approved labeling.

There is no current method-of-use exclusivity protecting a reimbursed intepirdine indication. A future developer would need to establish a new clinical and regulatory basis for any revival.

Which companies are challenging intepirdine?

No company is currently challenging intepirdine through a Paragraph IV filing or an Abbreviated New Drug Application. There is no active patent litigation involving a commercial intepirdine product.

The competitive threat came from established Alzheimer’s therapies and other investigational 5-HT6 antagonists rather than from generic manufacturers. Once MINDSET failed, the commercial rationale for a generic challenge disappeared because there was no approved product to substitute.

What is the market projection for intepirdine?

The current market projection is zero product revenue. Intepirdine has no approved indication, no commercial supply, no payer coverage, and no prescription base.

Before the MINDSET failure, the theoretical market opportunity was substantial because Alzheimer’s disease affects a large treatment population and symptomatic therapies can achieve broad prescribing. That opportunity did not convert into commercial value. Intepirdine would have entered a market dominated by generic donepezil, rivastigmine, and galantamine, with memantine used in moderate-to-severe disease. A premium price would have required clear incremental efficacy or tolerability, which the Phase 3 data did not establish.

Market factor Projection
U.S. launch probability under current status 0% absent a new development program
Current annual product revenue $0
Current prescription volume None
Current payer reimbursement None
Generic substitution risk Not applicable
Commercial value of existing clinical data Low
Value of a full redevelopment program Dependent on new efficacy evidence
Near-term revenue opportunity None

A hypothetical relaunch would require a new sponsor, renewed clinical development, a successful Phase 3 program, regulatory approval, manufacturing scale-up, and commercial positioning against low-cost generics and disease-modifying Alzheimer’s therapies. Those requirements make a near-term launch economically unattractive.

How does intepirdine compare with competing Alzheimer’s drugs?

Intepirdine was intended as a symptomatic oral therapy. Its competitive position differs from newer anti-amyloid antibodies, which target disease pathology and require biomarker selection, infusion infrastructure, and safety monitoring.

Drug or class Mechanism Regulatory status Commercial position
Intepirdine 5-HT6 antagonist Not approved No market
Donepezil Acetylcholinesterase inhibitor Approved Generic, low-cost standard
Memantine NMDA receptor antagonist Approved Generic, established use
Lecanemab Anti-amyloid antibody Approved in the U.S. Disease-modifying treatment with monitoring requirements
Donanemab Anti-amyloid antibody Approved in the U.S. Disease-modifying treatment with safety and diagnostic requirements

Intepirdine’s oral administration could have been commercially convenient, but convenience alone would not offset weak efficacy. The product would have faced generic competition from the outset unless it demonstrated a clinically meaningful improvement in cognition, function, dosing convenience, or adverse-event profile.

What patent litigation and settlement agreements affect intepirdine?

No active patent litigation, Paragraph IV case, or generic settlement agreement affects intepirdine. There is no known litigation timeline involving a marketed product, and no 30-month stay has been triggered under the Hatch-Waxman framework.

The absence of litigation is a consequence of the asset’s development failure, not evidence of a strong or weak enforceable patent estate. Patent disputes generally arise after approval and commercial launch, when an ANDA applicant has an economic reason to challenge listed patents. Intepirdine never reached that stage.

What manufacturing and intellectual-property barriers remain?

Manufacturing barriers are limited compared with biologic drugs because intepirdine is an oral small molecule. A future sponsor would likely face conventional requirements for active pharmaceutical ingredient production, formulation development, process validation, stability testing, and clinical supply.

The larger barriers are clinical and regulatory:

  1. Reproducing or improving efficacy after the failed MINDSET study.
  2. Selecting a patient population and endpoint strategy that can support approval.
  3. Demonstrating benefit over generic symptomatic therapy.
  4. Funding a new late-stage Alzheimer’s program.
  5. Establishing a commercially defensible price.

The compound’s small-molecule profile reduces manufacturing complexity but does not solve the clinical-validation problem.

How strong is the intepirdine patent estate?

The patent estate has low current commercial strength. Development-stage patent protection may restrict unauthorized use of particular chemical entities, formulations, or indications during the relevant patent term, but no approved product converts those rights into market exclusivity.

Patent-strength factor Assessment
Approved product anchor Absent
Orange Book protection Absent
Clinical validation Failed pivotal study
Generic litigation leverage None
Manufacturing complexity Moderate to low
Regulatory value Low
Redevelopment value Speculative and dependent on new data

Patent duration alone cannot support a positive valuation for intepirdine. The central asset risk is clinical failure rather than generic erosion.

What is the outlook for a generic launch?

There is no conventional generic-launch scenario because no branded intepirdine reference product exists. An ANDA applicant cannot launch a generic version of an unapproved product through the normal substitution pathway.

A future sponsor could develop intepirdine as a new drug, but that would require a full regulatory program rather than an abbreviated generic filing. Such a program would need to overcome the prior negative Phase 3 evidence and establish a differentiated benefit.

Key Takeaways

  • Intepirdine, or RVT-101, is a discontinued 5-HT6 antagonist for Alzheimer’s disease.
  • The Phase 3 MINDSET trial failed to improve cognition and daily functioning when added to donepezil.
  • Axovant ended development in September 2017.
  • Intepirdine has no FDA approval, Orange Book listing, marketed dosage form, or active commercial supply.
  • No Paragraph IV challenge, generic litigation, or settlement agreement affects the asset.
  • Current product revenue and market share are zero.
  • Patent rights have limited commercial value without approval or positive clinical data.
  • A relaunch would require a new sponsor and a new clinical development strategy, not a conventional generic application.
  • The near-term commercial projection is no launch and no revenue.

FAQs About Intepirdine

Is intepirdine still being developed for Alzheimer’s disease?

No. Axovant discontinued the program after the failed MINDSET Phase 3 trial, and no active clinical development program has replaced it.

Was intepirdine approved by the FDA?

No. Intepirdine never received FDA approval and has no approved Alzheimer’s disease indication.

Can patients obtain intepirdine through a generic pharmacy?

No. There is no approved or marketed intepirdine product available through retail, specialty, or mail-order pharmacies.

Did intepirdine fail because of safety problems?

The decisive issue was lack of efficacy in the pivotal MINDSET study. The trial failed its primary cognitive and functional endpoints, ending the commercial development program.

Could intepirdine be repurposed for another neurological disease?

A new indication would require a sponsor to generate fresh clinical evidence and obtain regulatory approval. No established repurposing program currently supports a commercial forecast.

References

  1. Axovant Sciences Ltd. (2017, September 26). Axovant announces topline results from the Phase 3 MINDSET study of intepirdine in Alzheimer’s disease.
  2. ClinicalTrials.gov. (n.d.). A study of RVT-101 in patients with mild-to-moderate Alzheimer’s disease: MINDSET study, NCT02585934. U.S. National Library of Medicine.
  3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
  4. U.S. Food and Drug Administration. (2023). Leqembi (lecanemab-irmb) approval information. FDA.
  5. U.S. Food and Drug Administration. (2024). Kisunla (donanemab-azbt) approval information. FDA.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.